Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ophtha.2022.07.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Summary of the National Advisory Committee on Immunization (NACI) Statement: Updated guidance on human papillomavirus (HPV) vaccines.
Can Commun Dis Rep
December 2024
Public Health Agency of Canada, Centre for Immunization and Respiratory Infectious Diseases, Ottawa, ON.
Background: Without vaccination, approximately 75% of people in Canada will acquire a human papillomavirus (HPV) infection in their lifetime. HPV vaccine coverage rates continue to fall short of the national goal of 90% coverage for two or more doses by 17 years of age. Recent evidence and World Health Organization (WHO) guidance now support a 1- or 2-dose schedule for younger age groups, which can simplify vaccination efforts and improve coverage rates compared to a multi-dose immunization program.
View Article and Find Full Text PDFPrevalence, Characteristics, and Distribution of Human Papillomavirus According to Age and HIV Status in Women of Eastern Cape Province, South Africa.
Viruses
November 2024
Department of Obstetrics and Gynaecology, Faculty of Health Sciences, Walter Sisulu University, Mthatha 5100, South Africa.
Article Synopsis
- - This study examined the prevalence and characteristics of cervical HPV among 325 women (ages 18-60) visiting a community health facility in Eastern Cape, South Africa, revealing an overall HPV prevalence of 65.2%, with the highest rates in younger women (80.9% in ages 18-25).
- - HPV infection rates showed a decline with age, particularly for high-risk HPV (HR-HPV) among all women and low-risk HPV (LR-HPV) among HIV-negative participants, but not among HIV-positive women.
- - A notable percentage of participants were infected with HPV types included in the Cervarix and Gardasil vaccines, highlighting a significant burden of HPV and suggesting the need for enhanced
Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in Mice.
Vaccines (Basel)
November 2024
Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China.
Background: Cervical cancer ranks as the fourth most common cancer affecting women globally, with HPV as the primary etiology agent. Prophylactic HPV vaccines have substantially reduced the incidence of cervical cancer.
Methods: This study assessed the immunogenicity of SCT1000, a 14-valent recombinant virus-like particle (VLP) vaccine developed by Sinocelltech, Ltd.
HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis.
Int J Cancer
November 2024
Clinical Medical Research Center, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
The presence of human immunodeficiency virus (HIV) infection increases the risk of acquiring human papillomavirus (HPV) infection and developing HPV-related adversities. We aimed to estimate the cost-effectiveness of HPV vaccination for women living with HIV in a Chinese setting. A decision-analysis Markov model was developed to estimate the cost-effectiveness of 36 HPV vaccination strategies for women living with HIV aged 18-45 years, from the healthcare system perspective.
View Article and Find Full Text PDFKNOWLEDGE AND PERCEPTION OF HUMAN PAPILLOMAVIRUS VACCINE AMONG ADOLESCENTS AND CAREGIVERS IN JOS METROPOLIS, PLATEAU STATE, NIGERIA.
West Afr J Med
November 2024
Professor of Community Medicine, University of Jos and Consultant, Jos University Teaching Hospital.
Introduction: HPV infection is well-recognized as a cause of nearly all cases of cervical cancer. There are currently three prophylactic HPV vaccines; a bivalent (Cervarix), a quadrivalent (Gardasil), and a nonavalent vaccine (Gardasil- 9). With the recent rollout of HPV vaccines in Nigeria, it is imperative to understand potential barriers and facilitators to its uptake.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!